Histone deacetylase (HDAC) inhibitors are an emerging class of anticancer agents that modify gene expression by altering the acetylation status of lysine residues of histone proteins, thereby inducing transcription, cell cycle arrest, differentiation, and cell death or apoptosis of cancer cells. In the clinical setting, treatment with HDAC inhibitors has been associated with delayed cardiac repolarization and in rare instances a lethal ventricular tachyarrhythmia known as torsades de pointes. The mechanism(s) of HDAC inhibitor-induced effects on cardiac repolarization is unknown. We demonstrate that administration of structurally diverse HDAC inhibitors to dogs causes delayed but persistent increases in the heart rate corrected QT interval (QTc), an in vivo measure of cardiac repolarization, at timepoints far removed from the T max for parent drug and metabolites. Transcriptional profiling of ventricular myocardium from dogs treated with various HDAC inhibitors demonstrated effects on genes involved in protein trafficking, scaffolding and insertion of various ion channels into the cell membrane as well as genes for specific ion channel subunits involved in cardiac repolarization. Extensive in vitro ion channel profiling of various structural classes of HDAC inhibitors (and their major metabolites) by binding and acute patch clamp assays failed to show any consistent correlations with direct ion channel blockade. Drug-induced rescue of an intracellular trafficking-deficient mutant potassium ion channel, hERG (G601S), and decreased maturation (glycosylation) of wild-type hERG expressed by CHO cells in vitro correlated with prolongation of QTc intervals observed in vivo. The results suggest that HDAC inhibitor-induced prolongation of cardiac repolarization may be mediated in part by transcriptional changes of genes required for ion channel trafficking and localization to the sarcolemma. These data have broad implications for the development of these drug classes and suggest that the optimal time to assess potentially transcriptionally mediated physiologic effects will be delayed relative to an epigenetic drug's T max /C max .
Histone deacetylases (HDACs) are divided into 4 classes including: class I (HDAC1, HDAC2, HDAC3, and HDAC8), Class IIa (HDAC4, HDAC5, HDAC7, and HDAC9), Class IIb (HDAC6 and HDAC10), Class III HDACs (sirtuins 1-7) and class IV (HDAC11). Class III HDACs are not inhibited by HDAC inhibitors and will not be discussed further. Each class is regionally expressed in the cell; specifically, Class I in the nucleus, Class IIa and IV in the nucleus and cytoplasm, and Class IIb in the cytoplasm. Class I HDACs principally regulate cell survival and proliferation whereas Class II HDACs exhibit tissue-specific roles. HDACs have also been associated with a number of well-characterized cellular oncogenes and tumor suppressor genes in various cancers (Mithraprabhu et al., 2013; Ropero and Esteller 2007; West and Johnstone 2014) .
HDAC inhibitors are an important emerging class of anticancer agents that induce hyperacetylation of lysine residues found on histones associated with nuclear chromatin and, for some compounds, nonhistone proteins found in the cytosol such as tubulin and heat shock protein 90 (HSP90) (Dokmanovic et al., 2007) . Hypoacetylation of histones induces a compacted chromatin structure and decreased gene expression whereas hyperacetylation causes the opposite effects. In the cytosol, hyperacetylation stabilizes tubulin and results in ubiquitination and degradation of HSP90, an important chaperone for a number of ion channel subunits and stabilization of tubulin. In cancer cells, these compounds induce transcription, cell cycle arrest, differentiation, cell death, and apoptosis. However, the effects of HDACi on normal cells, general physiology, and homeostasis are not as well understood. To date, the FDA has approved 4 HDAC inhibitors for the treatment of cutaneous T cell and/or peripheral T-cell lymphomas (vorinostat in 2006, romidepsin in 2009, belinostat in 2014) and more recently (in 2015) the FDA approved Farydak (panobinostat) for the treatment of multiple myeloma in combination with bortezomib and dexamethasone. Clinical trials of several other HDAC inhibitors, alone or in combination with other anti-cancer therapeutics, are ongoing for a variety of cancers (Yoon and Eom, 2016) .
There are 4 distinct structural classes of HDAC inhibitors: short chain fatty acids such as valproic acid and sodium butyrate, hydroxamic acids such as vorinostat, panobinostat and dacinostat, depsipeptides such as romidepsin, and benzamides such as mocetinostat (see Table 1 ). Hydroxamates are generally pan-HDAC inhibitors, whereas benzamides and depsipeptides lack appreciable HDAC6 activity, which is the only HDAC exclusively expressed in the cytosol. Although each structural class has different HDAC isoform specificity, they have very similar toxicity profiles in humans and animals. However, the observed toxicity profiles are somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents such as 5-azacytidine, which alters DNA methylation (Subramanian et al., 2010) .
Adverse events commonly observed with HDAC inhibitors include nausea/vomiting, fatigue, a transient decrease in platelet and white blood cell counts, and less commonly, variable effects on ECG waveform and prolongation of the heart rate corrected QT (QTc) interval, an in vivo measure of cardiac depolarization and repolarization derived from the electrocardiogram (ECG) (Lynch et al., 2012; Strevel et al., 2007; Subramanian et al., 2010) . Although prolongation of the QT interval can be inherited through the mutation of various potassium and/or sodium channels, QT interval prolongation can also be induced by administration of drugs predisposing patients to a potentially lethal cardiac tachyarrhythmia known as Torsades de Pointes (TdP). The best understood of these ion channels are the outward rectifying potassium channel Kv11.1 (encoded by hERG, Vandenberg et al., 2012) and the sodium channel Nav1.5 (Rampe and Brown, 2013) . Blockage of IKr (the potassium current underlying Kv11.1) was the most common cause of TdP reported with several marketed drugs that were subsequently withdrawn from the market (eg, terfenadine, astemizole and cisapride). Some drugs can cause QT prolongation and TdP by interfering with forward intracellular potassium ion channel trafficking from the endoplasmic reticulum to the Golgi apparatus and the cell surface, resulting in a functional blockade of repolarization over time (Harkcom and Abbott, 2010) . This latter mechanism, though less common than direct blockade of IKr, is observed with several drugs of varied pharmacological classes and structures (Wang, 2007) , such as geldanamycin (GDM) (HSP inhibitor), arsenic trioxide (antineoplastic leukemia drug), pentamidine (anti-protozoal), probucol (cholesterol-lowering) and fluoxetine (serotonin reuptake inhibitor).
Here we demonstrate that HDAC inhibitors of different structural classes and specificities cause time-dependent prolongation of myocardial ventricular repolarization in dogs, with concurrent transcriptional alterations of genes involved in protein trafficking and localization. These findings are further correlated with drug-induced restoration of a hERG trafficking deficient mutant (G601S) and decreased glycosylation (maturation) of Kv11.1 expressed in CHO cells, an example of one such ion channel. The data indicate that HDAC inhibitors may in part prolong cardiac repolarization through effects on transcription of genes involved in ion channel trafficking and localization to the sarcolemma.
MATERIALS AND METHODS

In vivo study design
During the initial course of typical oral drug development programs, Panobinostat, NVS050 and NVS060 were tested in dogs to assessed tolerability, toxicokinetics and potential effects on the ECG (collected by telemetry over 24 or 48 h). All dogs in each group were administered (by oral gavage): panobinostat (1.5 mg/ kg, N ¼ 3) every other day, NVS050 as consecutive (every other day) rising doses (0.03, 0.1, and 0.3 mg/kg, N ¼ 3) or NVS060 as consecutive rising doses (0.2 and 1.0 mg/kg, N ¼ 6).
To determine if the QTc interval-prolonging effects were only associated with the pan-HDAC hydroxamate structural class, competitor compounds of the same structural class (vorinostat, also known as SAHA) and the HDAC6-sparing benzamide (mocetinostat) were similarly profiled in dogs and compared with NVS050. To avoid the potential confounding effects of differences in oral bioavailability and to select doses for the main study, intravenous sighting studies were conducted. All dogs in each group (N ¼ 2/group) received a single dose of 0.2, 1, and 2 mg/kg NVS060; 0.05, 0.1, 0.2, and 0.25 mg/kg NVS050; 25 and 50 mg/kg vorinostat; and 10, 15, 25, and 40 mg/kg mocetinostat, respectively, at dose volumes ranging from 0.5 to 8 ml/kg administered intravenously as a slow bolus injection over approximately 2 minutes or longer. Mortality, clinical signs, body weight and food consumption were recorded and blood was taken for hematology, clinical biochemistry and toxicokinetics.
In the main study, naïve dogs (N ¼ 3/compound) were intravenously administered the vehicle(s) alone and single doses of each test compound at 2 dose levels (NVS050: 0.1 and 0.25 mg/ kg; vorinostat: 25 and 50 mg/kg; mocetinostat: 10 and 40 mg/kg), following an escalating-dose design. Electrocardiogram recordings via telemetry were collected for 24 h after each dosing occasion. Mortality, clinical signs and body weight were evaluated throughout the study. Blood was also sampled for toxicokinetics.
To further understand the impact of myocardial drug concentrations, dogs were challenged with the highest tested single doses of NVS050 (0.25 mg/kg), mocetinostat (40 mg/kg) and vorinostat (50 mg/kg) and euthanized at 17 h postdose (the time of maximal effects on QTc intervals). Cardiac samples were taken for the determination of drug concentrations, nuclear and cytosolic deacetylase activity and for transcriptional and western blot analyses. Cardiac samples were also taken from 3 vehicle treated male dogs for comparison.
Test formulations
The oral vehicle for all compounds was 0.5% (w/v) Methylcellulose, Type 400 cPs (viscosity). The parenteral vehicle for NVS050 was a mixture of 0.2 M tartaric acid, propylene glycol and phosphate-buffered saline (pH: 7.4). The parenteral vehicle for vorinostat consisted of 1 N NaOH, ethanol, 40% w/w hydroxypropyl-beta-cyclodextrine (HP-b-CD), 1 N HCl and aqua ad injectabile (sighting study) or 50% v/v HP-b-CD 40% and 50% v/ v aqua ad injectabile (main study). The parenteral vehicle for mocetinostat was a solution of 1 N HCl, 40% w/w HP-b-CD, 1 N NaOH and 0.9% NaCl. The parenteral vehicle for panobinostat was sterile water for injection (USP).
Animals
Dogs (male Beagles, Marshall Farms/BioResources) were 11-18 months (main study) of age and weighed up to 15 kg at the start of dosing. The dogs were housed and handled according to Institutional guidelines and SOPs. The studies were performed in conformity with the Swiss Animal Welfare Law and specifically under the Animal License 2240 by the Cantonal Veterinary Office, Basel Stadt or as approved by the animal care and use committee. Animal husbandry, handling and experimental telemetry procedures were in compliance with Institutional guidelines and SOPs, ICH guidelines and recommendations of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement (Hawkins et al., 2004; Morton, 2003) .
ECG telemetry and statistical analyses
The ECG was obtained from conscious dogs using biopotential leads.
For the intravenous NVS050, vorinostat and mocetinostat studies, non-invasive telemetry was used. ECG electrodes were placed on the clipped and shaved skin in ECG lead configurations II and rV2. Electrodes and electrode patches attached to the skin were covered by a jacket that contained the transmitter (emka Technologies). The dogs were trained to wear the jackets prior to the study.
For the oral NVS050, NVS060, and panobinostat studies, an implanted telemetry transmitter (D70-PCT, Data Science Heart rate and duration of PQ, QRS, and QT intervals were evaluated using the ECG Auto Analysis (emka Technologies) and Excel. The QT interval was adjusted for heart rate changes (QTc) using the population correction formula of Van de Water: QTc ¼ QT -0.087 (RR -1000) and/or an individual correction formula.
For each period, the QTc and other intervals (data not listed) were measured 4 times per hour (15-min intervals). Statistical tests were performed at the 0.05 significance level.
For the p.o. telemetry studies, the postdose measurements were adjusted for possible differences in baseline (predose) values by expressing the values as change from predose. Statistical analysis of the differences between test article and vehicle treatments were performed separately for each dosing occasion using individual averaged data of actual and baseline-adjusted values. A repeated-measures analysis of variance was applied to determine if significant differences existed between the dose groups with time, dose and time-dose interactions as fixed effects. Gaussian, linear, spherical, power, heterogeneous autoregression, compound symmetry, heterogeneous compound symmetry covariance structures were tested for each parameter. Based on group by time interaction, group means comparisons were assessed for each time point using t-tests on least-squares means. All statistical analyses were conducted using the SAS System for Windows (Release 8.2 SAS Institute, Cary, North Carolina).
For the i.v. telemetry studies with NVS050, mocetinostat and vorinostat, data between 0:15 and 19:30 were used; a second analysis was performed on data between 14:00 and 19:30 since it was assumed that an effect would mainly be seen in this interval. Data were analyzed using RMANCOVA method. The following effects were used in the repeated measurements model: treatment; animal number; time in hours post-treatment; interaction treatment versus time; baseline value (taken on a different day, at the same time of the day). For the covariance structure, an autoregression model for time in hours was used. All calculations were carried out on SAS, Version 9.2.2. For the analysis of variance (ANOVA) with repeated measurements, SAS Proc Mixed was used (SAS, 2011).
Postmortem sampling
Following anesthesia and exsanguination, transmural samples from left and right auricle and ventricle, and the interventricular septum were collected from the heart for histological processing, immunohistochemistry (standard and isopentane method) and genomics (myocardial tissue only). Additional samples for genomics were collected from the apex, sinoatrial node region, atrioventricular node/His bundle and Purkinje fibers with endocardium. Left ventricle tissue was sampled for test article concentration analysis.
Pharmacokinetics
The concentration of each drug was quantified in all individual dog heart and plasma samples using a tandem coupled mass spectrometry using electro spray ionization (LC MS/MS) method. Heart tissue samples were homogenized in methanol containing the labeled internal standard. After centrifugation, an aliquot of supernatant (heart tissue) or plasma was derivatized using a mixture of 3% phosphoric acid, propionic anhydride and methanol. An aliquot of the supernatant was injected onto a solid-phase extraction cartridge (hysphere C18 high-density cartridge, Spark Holland, Emmen, The Netherlands) connected online to a Inertsil OS-4 (100 Â 2.1 mm, 3 lm particles, GL Sciences). The compound was eluted with a gradient of 0.3% of formic acid in water versus acetonitrile/isopropanol (8:2 vol/vol) containing 0.3% (vol/vol) formic acid using a Symbiosis Pharma system (Spark Holland, Emmen, The Netherlands). The total flow rate was 0.4 ml/min. Detection was performed on an API 5000 triple quadrupole mass spectrometer from AB/Sciex (Foster City, California) equipped with a turbo ion spray source operated in the negative ion mode. Watson LIMS and Excel were used for data analysis and generation of pharmacokinetic parameters.
Microarrays for gene transcription and localization
Tissue samples of the left and right ventricles were immediately snap-frozen in liquid nitrogen and stored at approximately À80 C until processing. Total RNA was obtained by acid guanidinium thiocyanate-phenol-dichloromethane extraction from each frozen tissue section and the total RNA was then purified on an affinity resin (RNeasy, Qiagen). Total RNA was quantified by the absorbance at 260 nm, and the quality was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies). GeneChip microarray experiments were conducted using Canine Genome 2.0 Arrays (Affymetrix, Inc., Santa Clara, California, USA). Approximately 100 ng of total RNA was used to obtain mRNA using the 3 0 IVT express kit (Affymetrix). The Affymetrix MAS 5.0 software was used to scale the average intensity of each chip to a target intensity of 150. Principle component analysis (PCA, Partek Genomics Suite 6.4) was performed for visualization of differences in overall expression by treatment. Fold change values were calculated by comparing the raw expression values for samples from treated animals to controls using internal software, with raw values <20 set equal to 20 prior to fold change calculations. Up-or downregulated gene lists generally included only those probe sets where there was a !1.3-fold change in expression for treated versus controls, with P-value .01 by 1-way ANOVA with Benjamini Hochberg false discovery test correction.
Gene set enrichment analysis by gene ontology (GO, Gene Ontology Consortium, 2004) classification was performed using the DAVID Bioinformatics Resources 6.7 tool (http://david.abcc.ncifcrf. gov/) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. This was done by uploading the gene symbol for the human homologs to the dog genes of interest due to lack of comprehensive GO classification for the dog genome. This was done separately for the significantly affected genes for NVS050 and mocetinostat.
From the statistically significant probe sets, genes that were involved in protein transport/trafficking or localization were grouped together if up-or down-regulated. An average score for each compound was derived by taking the geometric mean of all fold-change values for that gene set.
HDAC enzymatic activity assay
Approximately 100 mg of left ventricle, right ventricle, septum, and apex were homogenized for nuclear and cytoplasmic protein extraction using the Covaris Ultrasonicator System (Covaris) and CelLytic NuCLEAR Extraction kit (Sigma). Tissues were snap-frozen in liquid nitrogen, pulverized by Covaris CryoPrep, and transferred into 1000 ml lysis buffer supplemented with protease and phosphatase inhibitor cocktails (Roche). Samples were subjected to Covaris Ultrasonicator for 2 nonconsecutive 60-s homogenization cycles (20% duty cycle; intensity 8; 200 cycles per burst). The homogenate was centrifuged at 11000 g for 20 min at 4 C. The resulting supernatant (cytoplasmic fraction) was collected and retained. The pellet was resuspended in extraction buffer supplemented with protease and phosphatase inhibitor cocktails for nuclear protein extraction. The samples were gently shaken at 4 C for 30 min, followed by centrifugation at 21000 g for 5 min. The supernatant was transferred as the nuclear fraction. Protein concentrations were measured by Coomassie Plus (Bradford) Assay Kit (Pierce). HDAC enzymatic activity was measured by SensoLyte 520 HDAC Activity Assay Kit (AnaSpec). For each reaction, 30 mg protein was diluted into a 96-well plate, incubated with HDAC substrate solution for 60 minutes at room temperature, and subjected to a plate reader (BioTek) for fluorescent signal detection at Ex/Em ¼ 490/520 nm. Reactions were set up in duplicate. The mean of each sample duplicate was taken and analyzed by Excel and GraphPad Prism 5 software, and statistical analysis was performed using Bonferroni's Multiple Comparison Test.
hERG assays HDAC inhibitors representing hydroxamate, benzamide, and depsipeptide structural classes were profiled in the acute hERG channel patch clamp and hERG-Lite channel trafficking assays at 1, 3, 10, and 30 lM.
hERG trafficking assay
Trafficking modulation was assessed by monitoring surface expression of the wild-type (WT) hERG channel as well as the rescue of surface expression of a hERG single mutant (SM) in an HEK293 cell antibody-based fluorescence assay as described by Wible et al. (2005) . Both cell lines express hERG channels with a reporter epitope engineered into the extracellular loop spanning transmembrane domains.
hERG expression and patch clamp electrophysiology (inhibition and maturation) HEK/hERG WT cells were recorded using patch pipettes filled with 100 mM K-aspartate, 20 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, and 10 mM HEPES, pH 7.2. The extracellular solution was 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4. hERG peak tail currents were induced by standard step-step voltage protocol for ca. 10 min. pCLAMP software (Axon Instruments) was used for generation of voltage-clamp protocols and data acquisition.
To study the long-term effects hERG currents, test articles were added to cell lines for 24 h (overnight) before recording. hERG currents were evaluated using IonWorks Quattro system (MDS Analytical Technologies) and the perforated patch technique with amphotericin B (100 mg/ml).
The glycosylation status of Kv11.1 was assessed in the above-noted HEK293 cell line that hyper-expresses wt-hERG and in a CHO cell-line that expresses Kv11.1 at much lower levels. Following overnight incubation with various HDAC inhibitors or GDM (Hsp90 inhibitor; positive control), hERG mRNA and Kv11.1 protein levels were determined.
RESULTS
In Vivo Cardiac Repolarization and Systemic Exposure
To determine if possible QTc interval prolonging effects would only be associated with the pan-HDAC hydroxamate structural class, competitor compounds of the same (vorinostat) and the HDAC6-sparing benzamide (mocetinostat) structural classes were similarly profiled and compared with hydroxamate HDAC inhibitors panobinostat, NVS050, and NVS060 in dog telemetry studies. Test articles were administered orally (NVS050, NVS060, and panobinostat) or intravenously (NVS050, vorinostat and mocetinostat) to mitigate the potential confounding effect of differences in oral bioavailability.
Across all studies of each compound, there were no overt treatment-related changes in ECG waveform morphology, rhythm, or P wave, PR, or QRS duration and the compounds were well tolerated; however, there were dose-dependent prolongations of the QTc interval that generally occurred at timepoints much later than the time of the maximal plasma concentrations of each drug (T max ) (Fig. 1) .
For panobinostat (Fig. 1A) , the QTc interval was prolonged (up to 11%) approximately 8-9 h after the first oral dose. After each subsequent dose, the onset was earlier (eg, approximately 5-h post-third dose) and the magnitude of QTc interval change was greater (up to 21%) and sustained for the remainder of the 24 h recording period. A mean maximal plasma concentration (C max ) of 97 nM was attained at 0.5 h (T max ) postdose of 1.5 mg/ kg panobinostat with no evidence of accumulation for up to 4 weeks. Based on plasma protein binding of 80%, the free C max at this dose was approximately 20 nM, which is approximately 170-fold lower than the IKr IC 50 (3.5 lM).
For NVS050 (Fig. 1B) , slight to moderate prolongation of QTc intervals was observed after single oral doses of 0.1 and 0.3 mg/ kg, but not at 0.03 mg/kg. At 0.1 mg/kg of NVS050, prolongation of mean QTc interval (þ9 ms; þ4%) was generally observed over the entire recording period, with a maximum mean QTc interval change of þ25 ms (þ12%). At 0.3 mg/kg, mean QTc interval prolongation of þ14 ms (þ7%) was evident from 10.5 hours postdose onwards, with a maximum mean QTc interval increase of þ36 ms (þ17%). At doses of 0.1 and 0.3 mg/kg of NVS050, C max values of 13 and 35 nM, respectively, were attained at 0.5 hours postdose. Based on plasma protein binding value of 80% for NVS050 in dogs, the free C max was approximately 7 nM following a dose of 0.3 mg/kg, which is approximately 4000-fold lower than the IC 50 of IKr (> 30 lM).
For NVS060 (Fig. 1C) , a single oral dose of 0.2 mg/kg produced slight increases in the QTc interval from approximately 8-18 h postdose of up to þ25 ms (þ11%), respectively, relative to the baseline vehicle control. Following 1 mg/kg NVS060, QTc interval prolongation was first observed approximately 11 h postdose onward, peaked at around 19 h postdose (þ54 ms, or þ23% relative to baseline vehicle controls) and did not completely return to baseline values through the end of recording period (48 h postdose). At doses of 1.0 mg/kg of NVS060, a mean C max value of 228 nM was attained at 0.5 hours postdose. Based on a plasma protein binding value of 55% for NVS060 in dogs, the free C max was approximately 103 nM following a dose of 1.0 mg/kg, which is > 290-fold lower than the IKr IC 50 (>30 lM).
Following intravenous administration of 0.1 and 0.25 mg/kg NVS050 ( Figure 1D ), QTc intervals were significantly prolonged from 6 h postdose onwards, with increasing amplitude towards the end of the recording interval. Maximal increases were in the range of þ18 ms (þ7%) at 0.1 mg/kg and þ40 ms (þ17%) at 0.25 mg/kg compared with time-matched vehicle control.
Following intravenous administration of vorinostat at 25 mg/ kg (Fig. 1E) , only slight and variable mean QTc interval prolongation was observed from approximately 9 h postdose until the end of the recording interval, when compared with predose and vehicle control values. However, following 50 mg/kg of vorinostat, a clear dissociation from the baseline curve was observed from 13.5 to 15 hours post-dose (approximately þ20 ms; þ8%). Although none of the QTc interval changes observed with vorinostat were statistically significant, maximal increases in QTc intervals following 50 mg/kg were greater than those observed at 25 mg/kg, thus suggesting a dose-response.
Following intravenous administration of 10 or 40 mg/kg mocetinostat (Fig. 1F ), significant prolongation of the QTc interval was observed from 14.5 h postdose onwards, with peak increases of þ10 ms (þ4%) and þ18 ms (þ7%), relative to baseline and vehicle control, respectively. When analyzed over the postdose recording period, the change in mean QTc interval between 10 and 40 mg/kg also attained statistical significance, thus indicating a dose-response.
As expected, following intravenous administration the C max of each compound was attained immediately after dosing, (Fig.  1 and Table 2 ).
Tissue Concentration and Nuclear and Cytosolic Deacetylase Activity in the Myocardium
At 17 h postdose, myocardial concentrations of NVS050, mocetinostat and vorinostat following single doses of 0.25, 40, and 50 mg/kg were 32nM, 22 nM, and below the limits of quantitation, respectively (Table 2 ). NVS050 and mocetinostat significantly inhibited HDAC activity in the left ventricle and apex from both nuclear and cytoplasmic fractions, commensurate when compared with Tmax, as shown by pharmacokinetic (PK) profiles and telemetry QTc data. QTc interval and PK data are depicted as the mean of N ¼ 3-6 per group. A, After each subsequent dose of Panobinostat, the onset of QTc interval prolongation was earlier and the magnitude greater (up to 21%). For each treatment day, QTc interval values were increased at all time points (P .05) compared with Control. B, NVS050 administered orally at 0.1 and 0,3 mg/kg as consecutive rising doses caused slight to moderate prolongation of QTc intervals of with a maximum mean change of þ25 and þ36 ms, respectively (P < .05 achieved after 18.5 h postdose). C, NVS060 administered orally as consecutive rising doses at 0.2 and 1 mg/kg led to increases in the QTc interval, from 8 to 11 h postdose of up þ25 ms (P < .05 from 8 to 17 h) and þ54 ms (P < .05 from 10.5 to 33.5 h), respectively. D, NVS050 administered intravenously as consecutive rising doses: QTc intervals were significantly (P .05) prolonged from 6 h postdose onwards, with maximal increases in the range of þ18 ms at 0.1 mg/kg and þ40 ms at 0.25 mg/kg compared with time-matched vehicle control.
E, Vorinostat administered intravenously as consecutive rising doses: at 25 mg/kg, variable mean QTc interval prolongation was observed from approximately 9 h onwards, whereas 50 mg/kg, was associated increases were observed from 13.5 to 15 h postdose (approximately þ20 ms, P > .05). F, Intravenous Mocetinostat prolonged QTc intervals (P .05) from 14.5 h postdose onwards, with peak increases of þ10 and þ18 ms following 10 and 40 mg/kg, respectively, relative to control.
with their myocardial concentrations (Fig. 2) . The trend was similar in the right ventricle and septum, although not reaching the level of statistical significance due to larger inter-sample variation (data not shown). Tissues from vorinostat-treated animals had HDAC enzyme activity levels similar to control tissue across all the subregions. HDAC enzyme activity was generally higher in the nuclear extract compared with cytoplasmic extract.
Gene Transcription and Localization
Principal component analysis of microarray results obtained from ventricular tissue from control and HDAC inhibitor-treated dogs shows a clear separation between the NVS050-and mocetinostattreated groups and control animals, while the vorinostat-treated group clustered very closely with the controls (Fig. 3) . The NVS050 and mocetinostat groups also separated from controls in different directions. Since the left and right ventricles showed very similar patterns of expression, these regions were combined for subsequent statistical analysis. NVS050 treatment resulted in the largest number of transcriptional changes, followed by mocetinostat (Fig.  4) . Little to no change was observed with vorinostat. Overall, approximately 20% of the significantly affected probe sets for NVS050 were also affected by mocetinostat.
Following GO gene set enrichment for NVS050 (Table 3 and Fig. 5 ), the top processes included protein transport and localization (including protein complex assembly), mitochondrial respiration and organization, RNA processing and translation, and protein folding and protein catabolism. Most of these were highly statistically significant. For mocetinostat (Table 3 and Fig. 5 ), protein transport and localization were also enriched, though to a lesser extent than with NVS050. There were similarities in the types of genes affected by NVS050 and mocetinostat, which included adaptor proteins (APs), ankyrins (ANK), vacuolar protein sorting (VPS) genes, tubulins, kinesin family members, Supplementary Table S1 ). There were a number of genes that showed altered expression levels with one compound, or were up-regulated by NVS050 but down-regulated by mocetinostat. For example, with NVS050, there was a clear up-regulation of genes associated with the early and late endosome, whereas mocetinostat treatment resulted in down-regulation of late endosomal genes, including a large number of the VPS genes. APs (eg, AP-2) at the clathrin-coated pit also showed differential expression as well, with up-regulation for NVS050 (including up-regulated clathrin) and down-regulation for mocetinostat. HDAC inhibition resulted in transcriptional changes in chaperone proteins such as Hsp70 and Hsp90 (Supplementary Table  S2) , with Hsp70 mRNA down-regulated and Hsp90 mRNA upregulated by NVS050 treatment. In addition, NVS050 treatment also resulted in the up-regulation of Hsp70 interacting protein ST13, stress-induced-phosphoprotein STIP1, and FK506 binding protein FKBP4. There was no effect of the HDAC6-sparing inhibitor mocetinostat on any of these genes.
NVS050 treatment also affected the expression of genes encoding proteins that are involved in the anchoring of ion channels to their proper locations within the sarcolemma. These included up-regulation of ANK3 (ankyrin-3 or ankyrin-G), and down-regulation of the ANK1-like and caveolin-3 (CAV3; LQT9) genes. For a summary of these transcriptional effects, please see Supplementary Table S3. hERG Inhibition, Trafficking, and Maturation In Vitro Of all compounds assessed (results Summarized in Table 4 ), only panobinostat showed moderate acute inhibition of IKr current with an IC 50 of approximately 3.5 lM. In the hERG-Lite assay, all HDAC inhibitors significantly increased expression of trafficking deficient G601S-hERG (Table 4 ) whereas biologically meaningful effects on WT-hERG were less apparent. Consistent with the potential effects on hERG trafficking seen in the G601S-hERG cellline, overnight incubation of NVS050 and dacinostat induced significant concentration-dependent decreases of IKr current comparable with the effects of GDM (Fig. 8) .
In CHO cells that express wt-hERG there were concentrationdependent increases in hERG mRNA and the immature core glycosylated 135 kDa form of Kv11.1 following overnight incubation with various HDAC inhibitors (Fig. 9) . The pan-HDAC inhibitors caused multiple Kv11.1 bands to migrate in the 155 KDa region, implying decreased glycosylation. Interestingly, HDAC6 sparing Mocetinostat consistently doubled the amount of hERG isoforms. Inhibition of Hsp90 by GDM had no effect on hERG mRNA levels in wt-hERG CHO cells, but did cause an overall decrease in Kv11.1 (protein).
In the HEK293 cells that overexpress wt-hERG at levels approximately 20-fold greater than the aforementioned CHO cells, HDAC inhibition had no consistent effects on relative hERG mRNA or protein expression (Fig. 10) .
DISCUSSION
All of the HDAC inhibitors assessed in these studies, regardless of structural class, caused a delayed QTc interval prolongation in dogs relative to the time of maximal plasma concentrations.
Of all the HDAC inhibitors tested, only panobinostat showed some moderate inhibition of IKr current in the manual patch clamp assay. However, maximal free plasma concentrations of panobinostat were 170-fold lower than the moderate IKr IC 50 (3.5 lM) inhibition seen in vitro. Overall, the delayed onset of QTc interval prolongation after p.o. and i.v. administration and the > 100-fold difference between free C max values and the IC 50 for direct inhibition of any ion channel for any compound supports the concept that the effects were mediated by alterations in ion channel trafficking, and not the result of direct ion channel blockade.
When tested at their maximum tolerated doses, the effects of each HDAC inhibitor on QTc interval duration can be ranked in the following order from greatest to least: NVS060 > panobinostat ! NVS050 > mocetinostat > vorinostat, which correlated with their HDAC potency and exposure (AUC) values. In this regard, the paucity of effects observed with vorinostat also correlated with its relatively weak potency (IC 50 100-to 1000-fold higher than the other HDAC inhibitors, depending on the assay), low volume of distribution and high clearance. In the case of NVS050 and mocetinostat, the QTc interval effect also correlated with their persistence in the myocardium and nuclear and cytosolic HDAC enzyme activity as measured at the peak time of QTc interval prolonging effect (approximately 17 h postdose). Myocardial concentrations of NVS050, mocetinostat and vorinostat following single doses of 0.25, 40, and 50 mg/kg correlated with their relative ranking for maximal effects on QTc interval (NVS050 > mocetinostat > vorinostat), but were well below concentrations that would have directly blocked any ion channels. Commensurate with their myocardial concentrations, NVS050 and mocetinostat significantly inhibited HDAC activity in the nuclear and cytoplasmic fractions of both the left ventricle and apex.
Of the 13 identified genes responsible for congenital long QT syndrome (cLQTS), many have been shown to encode for ion channel subunits that are misfolded and retained in the ER due to normal functional quality control mechanisms (Delisle et al., 2004) whereas others directly affect pore function of the ion channel (Harkcom and Abbott, 2010) . In addition, other forms of cLQTS are caused by mutations in proteins involved in cell SPENCE ET AL. | 47 trafficking and localization, such as ankyrin-B (ankyrin 2, LQT4), caveolin-3 (CAV3, LQT9), yotiao (AKAP9, LQT11), and a-1-syntrophin (LQT12) (Boudoulas and Mohler, 2011) . Localization of ion channels within the appropriate location in the sarcolemma (such as within the caveolae) or sarcoplasmic reticular membranes is required for their proper function (Hsiao et al., 2013) . This is made possible by the coordinated movement of channel proteins between cellular compartments through the process of membrane trafficking, using similar processes that are used for recycling or degradation of proteins through endocytosis (for reviews, see Balse et al., 2012; Smyth and Shaw, 2010) . Data from this study demonstrate that HDAC inhibitors of different structural classes (ie, hydroxamates and benzamides) can alter expression of several genes involved in trafficking, localization and insertion of proteins into the cell membrane. These include various tubulin isoforms responsible for forming the microtubule network along which vesicles containing newly formed proteins are transported from the ER to the Golgi, cytosol and cell surface, coat proteins that identify vesicles for anterograde (COPII, SEC24D) or retrograde (COPI) transport, motor proteins responsible for anterograde (kinesins) and retrograde (DYN) transport, small GTPases (Rabs) that play a role in vesicular sorting to various intracellular organelles, and proteins that are responsible for the insertion and anchoring of various ion channels into the cytoskeleton (ANK) and cell membrane (dystrophins and caveolins).
Although none of the primary ion channels associated with long QT syndrome were directly affected by HDACi treatment, other proteins that are known to complex with them were affected. For NVS050, this included upregulation of CAV3, which has been shown to associate with the hERG (KCNH2; LQT2) channel (Guo et al., 2012) and to be one of the genes responsible for long QT syndrome 9 (LQT9, Vaidyanathan et al., 2013) . CAV3 can also affect the late sodium current Nav1.5 (SCN5A; LQT3) (Vatta et al., 2006) by targeting the sodium channel to the intercalated disc of ventricular cardiomyocytes (Abriel, 2007) . Mocetinostat treatment resulted in an increase in SCN1B expression, which regulates SCN5A (Nav1.5; LQT3) expression and gating (Hu et al., 2012) . NVS050 treatment also affected the expression of genes encoding proteins that are involved in the anchoring of ion channels to their proper locations within the sarcolemma. These included up-regulation of ANK3 (ankyrin-3 or ankyrin-G) and downregulation of the ANK1-like gene. Although there are few literature reports on the function of this latter gene, another ankyrin gene, ANK2 (ankyrin-B) is required for targeting and stabilizing the sodium/calcium exchanger 1 in cardiomyocytes, and mutations in ANK2 are related to LQT4 (Kline and Mohler, 2006) . The more general effects on protein trafficking and localization observed with these compounds may have indirect effects on multiple ion channels that are involved in cardiac repolarization and may be responsible for the shared effects of HDAC inhibitors on cardiac repolarization.
Chaperone proteins such as the HSPs Hsp70/Hsc70 and Hsp90 affect Kv11.1 trafficking by facilitating the exit of the channel from the endoplasmic reticulum (Ficker et al., 2003) . HDAC inhibition resulted in transcriptional changes in Hsp70 and Hsp90, with Hsp70 mRNA down-regulated and Hsp90 mRNA up-regulated by NVS050 treatment. In addition, NVS050 treatment also resulted in the up-regulation of 2 APs that associate with Hsp70 and Hsp90, the Hsp70 interacting protein (ST13) and the stress-induced-phosphoprotein STIP1. Upregulation was also observed with the FK506 binding protein FKBP4, which also associates with Hsp90 and Hsp70 and plays a role in the intracellular trafficking of hetero-oligomeric forms of the steroid hormone receptors (Galigniana et al., 2001) . There was no effect of the HDAC6-sparing inhibitor mocetinostat on any of these genes, consistent with known role of HDAC6 in microtubule and Hsp90 acetylation and degradation.
Restoration of SM-hERG trafficking may be indicative of compounds that cause dysfunction of intracellular trafficking by acting as pharmacological chaperones to stabilize the mildly misfolded G601S channels in their correct conformation thereby allowing export from the ER and movement to the cell surface (Ficker et al., 2002; Zhou et al., 1999) or possibly altering ER quality control mechanisms, intracellular trafficking machinery and/or chaperone functions. Since none of these compounds appreciably bind hERG, the restoration of G601S induced by HDAC inhibitors appears to be mediated by transcriptional dysregulation of proteins involved in ion channel trafficking and/or quality control mechanisms within the endoplasmic reticulum. Consistent with the effects on ion channel trafficking, overnight incubation of NVS050 and dacinostat induced significant concentration-dependent decreases of the IKr current comparable with the effects of GDM.
Kv11.1 (the protein encoded by hERG) is considered to exist naturally in two states of glycosylation, an immature core glycosylated state (135 kDa) that is generally retained within the ER and a mature fully glycosylated state (155 kDa) that is attained following trafficking of the immature channel from the ER via its chaperones Hsp90 and Hsp70 to the Golgi apparatus (Ficker, 2003) . The fully glycosylated form of Kv11.1 is then trafficked from the Golgi to the cytosol and cell surface where it regulates repolarization. Therefore, the glycosylation status of Kv11.1 was assessed in the above-noted HEK293 cell line that hyperexpresses wt-hERG and in a CHO cell-line that expresses Kv11.1 at much lower levels and is considered more representative of expression levels observed in cardiomyocytes. When CHO cells that expressed wt-hERG were incubated overnight with HDAC inhibitors, there were concentration-dependent increases in hERG mRNA and the immature core glycosylated 135 kDa form of Kv11.1 (Fig. 9) . The results indicate that HDAC inhibition increased transcription of hERG mRNA with a commensurate increase in translation of Kv11.1 protein that was unable to traffic to the Golgi apparatus to complete glycosylation to the mature 155 KDa form. The pan-HDAC inhibitors also caused multiple Kv11.1 bands to migrate in the 155 KDa region, indicating that pan-HDAC inhibition may have induced multiple states of Kv11.1 hypo-glycosylation. Interestingly, the HDAC6-sparing benzamide mocetinostat consistently doubled the overall expression of both forms of hERG, suggesting that some of the maturational effects seen with the other pan-HDAC inhibitors may have been due inhibition of cytosolic lysine deacetylases, although similar effects were not seen Romidepsin, which also lacks appreciable HDAC6 activity. As expected, inhibition of Hsp90 by GDM had no effect on hERG mRNA levels in wt-hERG CHO cells, but did cause an overall decrease in Kv11.1, likely due to its increased degradation in the cytosol as observed by Ficker et al. (2003) . In the HEK293 cells that overexpress wt-hERG at levels approximately 20-fold greater than the aforementioned CHO cells, HDAC inhibition had no effects on relative hERG mRNA or protein expression. These effects are not entirely novel since sodium butyrate, a weak HDAC inhibitor commonly used in the production of recombinant proteins and antibodies, increases protein production in CHO > HEK cells through histone acetylation and transcriptional de-repression (Jeon and Lee, 2007) . Butyrate has also been shown to diminish the amount and quality of glycosylation (Sung, 2004) . Alternatively, given the extremely high basal expression of Kv11.1 in these HEK cells (20-fold higher than CHO cells) it is possible that transcription of hERG expression was already at a maximum and unlikely to be further In the absence of appreciable hERG binding, the restoration of G601S-hERG trafficking in HEK293 cells combined with the accumulation of immature core glycosylated wt-hERG in CHO cells indicates that the microtubule quality control mechanism in the ER was affected by all HDAC inhibitors regardless of HDAC isotype specificity, and also suggests that dysregulation of this ER quality control mechanism likely occurred through a transcriptionally-mediated mechanism. Futhermore, Smith and McBride (2011) showed that trafficking of G601S-hERG is negatively regulated by a microtubule-dependent compartment within the ER. The effects on G601S-hERG compared with wthERG were differentially regulated by nocodazole, a drug that causes the depolymerization of microtubules and disrupts the organization of pre-Golgi QC compartments without altering the overall distribution of the ER and without acting as a pharmacological chaperone. The consistent trends in increased G601S-hERG expression observed with all HDAC inhibitors, including HDAC6-sparing inhibitors, in the HEK cell line was similar to the effects observed with nocodazole and indicate that such effects may be caused by a common downstream mechanism that is mediated through transcriptional effects on cytosolic proteins involved in protein transport and insertion into the cell membrane. This hypothesis is further supported by the transcriptomic assessment of myocardial samples taken following treatment with NVS050 and mocetinostat. The collective paucity of acute effects of any HDAC inhibitor on the IKr current and other ion channels, as measured by competitive binding inhibition and acute functional patch-clamp assays, further indicated that these effects are not due to direct interaction with Kv11.1 or other ion channels involved in repolarization.
Some of the differences observed between NVS050 and mocetinostat are likely due to their different relative potencies for the various HDAC isoforms. Although all HDAC inhibitors developed to date have activity against the class I HDAC enzymes, they have variable activity against the other HDAC isoenzymes. For example, the hydroxamates are considered pan-HDAC inhibitors, whereas the benzamides and romidepsin generally lack appreciable activity for class II HDACs (especially HDAC6). HDAC6 is known to deacetylate Hsp90, a cytosolic SPENCE ET AL. | 51 chaperone of several proteins including ion channels such as Kv11.1. Acetylation of Hsp90 disrupts its chaperone function and results in ubiquitination and degradation of its client proteins. HDAC6 also deacetylates a-tubulin and HDAC6 inhibition results in tubulin acetylation and microtubule stabilization (Tran et al., 2007) . Collectively, such effects are expected to inhibit proper folding of nascent proteins formed in the ER and decrease intracellular trafficking to the Golgi and cell surface. Given this, it is somewhat surprising that QTc interval prolongation has been observed clinically across all of the above-noted structural classes of HDAC inhibitors, including the HDAC6-sparing inhibitors entinostat and romidepsin (Kim and Bae, 2011; Piekarz et al., 2006) .
The delayed effects on cardiac repolarization and Kv11.1 maturation (hypo-glycosylation) described in these studies are consistent with drugs that cause intracellular ion channel trafficking defects from the endoplasmic reticulum, Golgi apparatus, cytosol and ultimately the sarcolemma of cardiomyocytes. This is supported by the fact that some HDAC inhibitors and GDM can decrease the IKr current following overnight incubation to a degree similar to GDM (a known hERG trafficking inhibitor, see Wang, 2007) . The HDAC inhibitor-mediated dysregulation of transcription of genes required for normal intracellular protein trafficking and insertion into the cell membrane is uniquely different compared with drugs that directly inhibit ion channel function by blocking the ion channel pore or by affecting trafficking through direct binding to nascent ion channel subunits and/or disruption of ion channel chaperones such as Hsp90 and or Hsp70. In view of the described transcriptional dependence of HDAC inhibitors, effects on cardiac repolarization are expected to take more time to manifest than that of the typical mechanisms described above. As such, the clinical paradigm of assessing cardiac repolarization via ECGs only collected at time points approximating the C max /T max , as is typically done during Thorough QT/QTc Studies, would be inappropriate for such drugs. Based on the results of this study, a longer duration of ECG monitoring should be considered for drugs with an epigenetic mode of action. Given the known reverse rate dependence of the QTc interval and risk of proarrhythmia (Dorian and Newman, 2000; Hondeghem, 2008) , delayed effects on cardiac repolarization may be of greatest concern if the maximum effects on ion channel expression at the cell membrane would be expected at time of rest or early awakening (Peckova et al., 1998) . Although the cardiac effects of HDAC inhibitors have been largely managed through the alteration of dose and regimen, these data may further inform the clinical exclusion criteria and monitoring strategies used for related epigenetic drugs and encourage greater vigilance to avoid concomitant use of drugs that are already known to prolong the QT interval. These data also have broad implications for the development of these and other epigenetic drug classes.
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